New Website
We are very excited to announce the launch of our newly designed website. Our goal with this new website is to provide our visitors with a more comprehensive grasp...
News
Pivotal to collaborate with Checkpoint Therapeutics on a study in patients with cutaneous squamous cell carcinoma
- Global trial has recently expanded to Western Europe with the first European sites now initiated
- Collaboration will enable patients in Europe to access PD-L1 inhibitor to treat cSCC not...
Highlight Therapeutics & Pivotal advance into a phase IIa to examine gastro-intestinal cancer therapy
- Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in patients with liver metastasis from colorectal or gastric/gastro-esophageal junction cancers
- First cohort of 11 patients already...
We have successfully deployed Azure Devops software
We have deployed Azure DevOps Software as a Service
It has been validated in compliance with 21 CFR part 11 to be used to manage system development lifecycle. Over the last...
Release of Oracle Clinical version 5.2
We have released Oracle Clinical version 5.2 in a fully qualified Azure Cloud Environment
The Oracle Clinical version 5.2 is in compliance with 21 CFR part 11. “Oracle Clinical...
We have successfully completed our Cloud Computing Journey
We operate in a fully qualified Azure Cloud Environment. We host all of our applications and services in compliance with 21 CFR part 11. "Microsoft Azure, with its flexibility and...
Adaptive study design and the potential for convalescent plasma therapy in Covid-19 patients
ID-HUB media spoke with José Javier García, Pivotal´s VP, Data Management and Biostatistics, about adaptive study design and the potential for convalescent plasma therapy in Covid-19 patients
To read the...
Staidson and Pivotal to collaborate in European Clinical trial of progressive severe Covid-19 patients
- The phase II, multicenter, open-label, randomized and controlled clinical trial will research whether BDB-001, a recombinant injectable humanized anti-human C5a monoclonal antibody, has a promising role in the treatment...
Pivotal´s collaboration with children´s vaccination in the poorest countries
Pivotal has adhered to the Alliance for Children´s Vaccination
Pivotal collaborates along with Gavi, an international organization and global Vaccine Alliance, in the fight...